Expression of neuropeptide Y, omentin and visfatin in visceral and subcutaneous adipose tissues in humans: Relation to endocrine and clinical parameters

Obesity Facts

Volumn 3, Issue 4, 2010, Pages 245-251

  Barth, Stephanie ^a   Klein, Peter ^b   Horbach, Thomas ^b,c   Dötsch, Jörg ^d   Rauh, Manfred ^a   Rascher, Wolfgang ^a   Knerr, Ina ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Department of Surgery General Hospital   (Germany)

^d UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Adipose tissue; Neuropeptide Y; Obesity; Omentin; Visfatin

Indexed keywords

GLIBENCLAMIDE; GLUCOCORTICOID; GLUCOSE; HYDROCORTISONE; INSULIN; METFORMIN; NEUROPEPTIDE Y; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OMENTIN; PROTEIN; UNCLASSIFIED DRUG; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INTRAABDOMINAL FAT; MALE; MASS SPECTROMETRY; METABOLITE; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; REAL TIME POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; SURGICAL PATIENT; URINALYSIS; BLOOD; ENDOCRINE SYSTEM; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; URINE;

ADULT; CYTOKINES; ENDOCRINE SYSTEM; FEMALE; GENE EXPRESSION; GPI-LINKED PROTEINS; HUMANS; HYDROCORTISONE; INTRA-ABDOMINAL FAT; LECTINS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; OBESITY; SUBCUTANEOUS FAT;

EID: 77956555952     PISSN: 16624025     EISSN: 16624033     Source Type: Journal    
DOI: 10.1159/000319508     Document Type: Article

References (45)

1. Bessesen DH: Update on obesity. J Clin Endocri-nol Metab 2008;93:2027-2034.
2. Alastair JJ, Wood MD: Obesity. N Engl J Med 2002;346:591-602.
3. Sorof J, Daniels S: Obesity Hypertension in children. Hypertension 2002;40:441-447.
4. Meigen C, Keller A, Gausche R, Kromeyer-Hauschild K, Blüher S, Kiess W, Keller E: Secular trends in body mass index in German children and adolescents: a cross-sectional data analysis via CrescNet between 1999 and 2006. Metabolism 2008;57:934-939.
5. Rudolf MCJ, Sahota P, Barth JH, Walker J: Increasing prevalence of obesity in primary school children: cohort study. BMJ 2001;322:1094-1095.
6. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, et al: Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724-1737.
7. Knerr I, Herzog D, Rauh M, Rascher W, Horbach T: Leptin and ghrelin expression in adipose tissues and serum levels in gastric banding patients. Eur J Clin Invest 2006;36:389-394.
8. Baltatzi M, Hatzitolios A, Tziomalos K, Iliadis F, Zamboulis CH: Neuropeptide Y and alpha-melanocyte-stimulating hormone: interaction in obesity and possible role in the development of hypertension. Int J Clin Pract 2008;62:1432-1440.
9. Sulyok E, Tulassay T: Natriuresis of fasting: the possible role of leptin-neuropeptide Y system. Med Hypotheses 2001;56:629-633.
10. Chronwall BM: Anatomy and physiology of the neuroendocrine arcuate nucleus. Peptides 1985;6 (suppl 2):1-11.
11. ODonohue TL, Chronwall BM, Pruss RM, Mezey E, Kiss JZ, Eiden LE, Massari VJ, Tessel RE, Pickel VM, DiMaggio DA, et al: Neuropep-tide Y and peptide YY neuronal and endocrine system. Peptides 1985;6:755-768.
12. Kos K, Harte A, James S, Snead D, OHare J, McTernan P, Kumar S: Secretion of neuropeptide Y in human adipose tissue and its role in maintenance of adipose tissue mass. Am J Physiol Endo-crinol Metab 2007;293:E1335-1340.
13. Kuo L, Kitlinska J, Tilan J, Li L, Baker S, Johnson M, Lee E, Burnett M, Fricke S, Kvetnansky R, Herzog H, Zukowska Z: Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007;13:803-811.
14. Hanko JH, Tornebrandt K, Hardebo JE, Kalstrom J, Nobin A, Owman CH: Neuropeptide Y induces and modulates vasoconstriction in intracranial and peripheral vessels of animals and men. J Auton Pharmacol 1986;52:175-179.
15. Abe, K, Tilan JU, Zukowska Z: NPY and NPY receptors in vascular remodeling. Curr Top Med Chem 2007;7:1704-1709.
16. Crown A, Clifton DK, Steiner RA: Neuropeptide signaling in the integration of metabolism and reproduction. Neuroendocrinology 2007;86:175-182.
17. Lettgen B, Wagner S, Hänze J, Lang RE, Rascher W: Elevated plasma concentration of neuropeptide Y in adolescents with primary hypertension. J Hum Hypertens 1994;8:345-349.
18. Knerr I, Dittrich K, Miller J, Kummer W, Rösch W, Weidner W, Rascher W: Alteration of neuro-nal and endothelial nitric oxide synthase and neu-ropeptide Y in congenital ureteropelvic junction obstruction. Urol Res 2001;29:134-140.
19. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al: Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
20. Smith FJ, Campfield LA, Moschera JA, Ballon PS, Burn P: Feeding inhibition by neuropeptide Y. Nature 1996;382:307.
21. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC, Gong DW: Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 2006;290:E1253-1261.
22. De Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M, Fried SK, Gong DW, Shuldiner AR, Pollin TI, McLenithan JC: Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007;56:1655-1661.
23. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hira-matsu R, Matsuzawa Y, Shimomura I: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005;307:426-430. (Pubitemid 40139988)
24. Gualillo O, Gonzlez-Juanatey JR, Lago F: The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007;17:275-283.
25. Revollo JR, Körner A, Mills KF, Satoh A, Wang T, Garten A, Dasgupta B, Sasaki Y, Wolberger C, Townsend RR, Milbrandt J, Kiess W, Imai S: Nampt/PBEF/Visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007;6:363-375.
26. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294:2166-2170.
27. Rascher W, Kremens B, Wagner S, Feth F, Hun-neman DH, Lang RE: Serial measurements of neuropeptide Y in plasma for monitoring neuro-blastoma in children. J Pediatr 1993;122:914-916.
28. Bald M, Gerigk M, Rascher W: Elevated plasma concentrations of neuropeptide Y in children and adults with chronic and terminal renal failure. Am J Kidney Dis 1997;30:23-27.
29. Knerr I, Dachert C, Beinder E, Metzler M, Dötsch J, Repp R, Rascher W: Adrenomedullin, calcitonin gene-related peptide and their receptors: evidence for a decreased placental mRNA content in pre-eclampsia and HELLP syndrome. Eur J Obstet Gynecol Reprod Biol 2002;101:47-53.
30. Yu V, Tudor Y, Hale C, Plant M, Kim KW, Wang M, Nguyen Y, Miguel TS, Chen M, Nybo R, Baum-gartner J, Kurzeja RJ, Powers D: High capacity homogeneous non-radioactive cortisol detection assays for human 11beta-hydroxysteroid dehy-drogenase type 1. Assay Drug Dev Technol 2007; 5:105-115.
31. Plank C, Meiner U, Rauh M, Wollmann H, Dörr HG, Rascher W, Dötsch J: Cortisol-cortisone ratios in small for gestational age (SGA) children without postnatal catch-up growth. Clin Endocrinology 2007;67:304-309.
32. National Task Force on the Prevention and Treatment of Obesity: Overweight, obesity, and health risk. Arch Intern Med 2000;160:898-904.
33. Montague CT, ORahilly S: The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000;49:883-888.
34. Stephens TW, Basinski M, Bristow PK, Bue-Valleskey JM, Burgett SG, Craft L, Hale J, Hoffmann J, Hsiung HM, Kriauciunas A, et al: The role of neuropeptide Y in the antiobesity action of the obese gene product. Nature 1995;377:530-532.
35. Walker PH, Grouzmann E, Burnier M, Wheber B: The role of neuropeptide Y in cardiovascular regulation. Trends Pharmacol Sci 1991;12:111-115.
36. Fain JN, Sacks HS, Buehrer B, Bahouth SW, Garrett E, Wolf RY, Carter RA, Tichansky DS, Madan AK: Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond) 2008;32:810-815.
37. Revollo JR, Grimm AA, Imai S: The NAD biosynthesis pathway mediated by nicotinamide phosphori-bosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem 2004;279:50754-50763.
38. Samal B, Sun Y, Stearns G, Xie C, Suggs S, Mc-Niece I: Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol 1994;14:1431-1437.
39. Arner P: Visfatin - a true or false trail to type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91:28-30.
40. Stephens JM, Vidal-Puig AJ: An update on visfa-tin/pre-B cell colony-enhancing factor, an ubiquitously expressed, illusive cytokine that is regulated in obesity. Curr Opin Lipidol 2006;17:128-131.
41. Sethi JK: Is PBEF/visfatin/Nampt an authentic adi-pokine relevant to the metabolic syndrome? Curr Hypertens Rep 2007;9:33-38.
42. Blakemore AI, Meyre D, Delplanque J, Vatin V, Lecoeur C, Marre M, Tichet J, Balkau B, Froguel P, Walley AJ: Rare variant in the visfatin gene (NAMPT/PBEF1) is associated with protection from obesity. Obesity 2009;17:1549-1553.
43. Travison TG, ODonnell AB, Araujo AB, Mat-sumoto AM, McKinlay JB: Cortisol levels and measures of body composition in middle-aged and older men. Clin Endocrinol 2007;67:71-77.
44. Purnell JQ, Kahn SE, Samuels MH, Brandon D, Loriaux DL, Brunzell JD: Enhanced cortisol production rates, free cortisol, and 11beta-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. Am J Physiol Endocrinol Metab 2009;296:E351-357.
45. Eyzaguirre F, Mericq V: Insulin resistance markers in children. Horm Res 2009;71:65-74.